Clinical trials in cancer screening, prevention and early diagnosis (SPED): a systematic mapping review

Background Global annual cancer incidence is forecast to rise to 27.5 M by 2040, a 62% increase from 2018. For most cancers, prevention and early detection are the most effective ways of reducing mortality. This study maps trials in cancer screening, prevention, and early diagnosis (SPED) to identif...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:BMC cancer Ročník 23; číslo 1; s. 1 - 11
Hlavní autori: O’Dowd, Emma L., Merriel, Samuel W. D., Cheng, Vinton W. T., Khan, Sam, Howells, Lynne M., Gopal, Dipesh P., Roundhill, Elizabeth A., Brennan, Paul M., Crosbie, Philip A. J., Neal, Richard D., Brown, Karen, Crosbie, Emma J., Baldwin, David R.
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: London BioMed Central 04.09.2023
BioMed Central Ltd
Springer Nature B.V
BMC
Predmet:
Asia
Biomedical and Life Sciences
Biomedicine
Breast cancer
Cancer
Cancer Research
Cancer screening
Cancer therapies
Cervical cancer
Clinical trials
Demographic aspects
Diagnosis
Early detection of cancer
Economic aspects
Geographical distribution
Health aspects
Health care disparities
Health care policy
Health Promotion and Disease Prevention
Intervention
Liver cancer
Mapping
Medical research
Medical screening
Medicine/Public Health
Mortality
Observational studies
Oncology
Oncology, Experimental
Prevention
Research funding
Screening
Social aspects
Surgical Oncology
Systematic mapping
Trials
Tumors
United Kingdom
Asia
United Kingdom
North America
Europe
Africa
Prevention
Screening
Early detection of cancer
Trials
Systematic mapping
Cancer
ISSN:1471-2407, 1471-2407
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Background Global annual cancer incidence is forecast to rise to 27.5 M by 2040, a 62% increase from 2018. For most cancers, prevention and early detection are the most effective ways of reducing mortality. This study maps trials in cancer screening, prevention, and early diagnosis (SPED) to identify areas of unmet need and highlight research priorities. Methods A systematic mapping review was conducted to evaluate all clinical trials focused on cancer SPED, irrespective of tumour type. The National Cancer Research Institute (NCRI) portfolio, EMBASE, PubMed and Medline were searched for relevant papers published between 01/01/2007 and 01/04/2020. References were exported into Covidence software and double-screened. Data were extracted and mapped according to tumour site, geographical location, and intervention type. Results One hundred seventeen thousand seven hundred one abstracts were screened, 5157 full texts reviewed, and 2888 studies included. 1184 (52%) trials focussed on screening, 554 (24%) prevention, 442 (20%) early diagnosis, and 85 (4%) a combination. Colorectal, breast, and cervical cancer comprised 61% of all studies compared with 6.4% in lung and 1.8% in liver cancer. The latter two are responsible for 26.3% of global cancer deaths compared with 19.3% for the former three. Number of studies varied markedly according to geographical location; 88% were based in North America, Europe, or Asia. Conclusions This study shows clear disparities in the volume of research conducted across different tumour types and according to geographical location. These findings will help drive future research effort so that resources can be directed towards major challenges in cancer SPED.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
ISSN:1471-2407
1471-2407
DOI:10.1186/s12885-023-11300-8